TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12109627

Group type: EXPERIMENTAL
Intervention: 2 mg of oral 17beta E2 daily (group A)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 2 mg E2 daily plus 5 mg daily oral dydrogesterone (group B)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 2 mg E2 and 10 mg dydrogesterone (group C)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 10674879

Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide 100 mg m(‐2) p.o. days 1‐14, fluorouracil 500 mg m(‐2) i.v. days 1 and 8, epirubicin 30 mg m(‐2) i.v. days 1 and 8)
Number of subjects: 151

Group type: COMPARATOR
Intervention: CNF (cyclophosphamide 100 mg m(‐2) p.o. days 1‐14, fluorouracil 500 mg m(‐2) i.v. days 1 and 8, mitoxantrone 6 mg m(‐2) i.v. days 1 and 8)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: CEF
Number of subjects: 151

Group type: COMPARATOR
Intervention: CNF
Number of subjects: 151
Study: 9499814

Group type: EXPERIMENTAL
Intervention: Histamine challenge after beta 2‐agonist pre‐treatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bronchial histamine and methacholine challenges (HiCh/MeCh)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bronchial challenges (HiCh/MeCh)
Number of subjects: 10
Study: 1870041

Group type: EXPERIMENTAL
Intervention: Hypodermoclysis with hyaluronidase (250 U)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hypodermoclysis without hyaluronidase
Number of subjects: 12
Study: 6467496

Group type: EXPERIMENTAL
Intervention: Levonantradol
Number of subjects: 57

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 57
Study: 31464392

Group type: EXPERIMENTAL
Intervention: Micronutrient pack
Number of subjects: 49
Study: 29051325

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg every 4 weeks (2q4)
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg every 8 weeks after five initial monthly doses (2q8)
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2q4 and 2q8 pooled)
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 748

Group type: COMPARATOR
Intervention: Macular laser photocoagulation
Number of subjects: 748
Study: 26687984

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 2331

Group type: COMPARATOR
Intervention: Medical therapy without exercise training (Control)
Number of subjects: 2331
Study: 25249397

Group type: EXPERIMENTAL
Intervention: Methotrexate plus adalimumab (DMARD + ADA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Methotrexate plus placebo (DMARD)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: High baseline CXCL13 levels
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: CXCL13 plasma levels
Number of subjects: 76
Study: 22706204

Group type: EXPERIMENTAL
Intervention: Fluoride concentration at 20 mg/l
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Fluoride concentration at 10 mg/l
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Fluoride concentration at 5 mg/l
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Fluoride concentration at 2.5 mg/l
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Fluoride concentration at 0 mg/l
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Fluoridated milk at 60°C
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Fluoridated milk at 22°C
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Fluoridated milk at 4°C
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 20 mg/l
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 10 mg/l
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 5 mg/l
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 2.5 mg/l
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 0 mg/l
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 60°C
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 22°C
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 4°C
Number of subjects: 126
Study: 20844179

Group type: EXPERIMENTAL
Intervention: Rotating-platform design (mobile-bearing)
Number of subjects: 273

Group type: COMPARATOR
Intervention: All-polyethylene tibial component (fixed-bearing)
Number of subjects: 273
Study: 16988647

Group type: EXPERIMENTAL
Intervention: 50 g xylitol in water
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 35 g xylitol in water
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 50 g erythritol in water
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 20 g erythritol in water
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 35 g erythritol in water
Number of subjects: 70

Group type: COMPARATOR
Intervention: 45 g sucrose
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Comparison of xylitol and erythritol
Number of subjects: 70
Study: 18003959

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg once daily)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Alendronate (10 mg once daily)
Number of subjects: 428
Study: 15286097

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg as a single oral dose
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ximelagatran 36 mg twice daily for 5 days plus a 40 mg oral dose of atorvastatin on day 4
Number of subjects: 16
Study: 10772054

Group type: EXPERIMENTAL
Intervention: Medtronic Hall tilting disc valve (MH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: St. Jude Medical bileaflet valve (SJM)
Number of subjects: 24
Study: 9069575

Group type: EXPERIMENTAL
Intervention: 4 mg i.v. ondansetron
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study: 8260695

Group type: EXPERIMENTAL
Intervention: EVDAC regimen (high-dose epirubicin, vincristine, dexamethasone, followed by cyclophosphamide and high-dose cytarabine)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: EVDAC regimen
Number of subjects: 54
Study: 2408848

Group type: EXPERIMENTAL
Intervention: Baseline EMG activity variations
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Median nerve stimulus voltages
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: H/M ratio less than 50%
Number of subjects: 4
Study: 995040

Group type: EXPERIMENTAL
Intervention: Mazindol (2 mg one hour before lunch)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31251679

Group type: EXPERIMENTAL
Intervention: Foreign Language (FL) learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Games
Number of subjects: 0

Group type: COMPARATOR
Intervention: Music appreciation
Number of subjects: 0
Study: 29972516

Group type: EXPERIMENTAL
Intervention: Standard Operating Procedure (SOP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unit Routine Decubitus (URD)
Number of subjects: 30
Study: 26031908

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis (BB‐12(®)) at a dose of 10(9) CFU
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 24923723

Group type: EXPERIMENTAL
Intervention: 1 week hemifield eye patching and daily sessions of optokinetic stimulation (n=11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No neglect-specific treatment (n=10)
Number of subjects: 21
Study: 22722637

Group type: EXPERIMENTAL
Intervention: Herbal Fufang (10 g/day, twice per day, n = 101)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo (n = 93)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Herbal Fufang (n = 101)
Number of subjects: 194
Study: 20842051

Group type: EXPERIMENTAL
Intervention: CpG loaded virus-like nanoparticles vaccine
Number of subjects: 22
Study: 17508528

Group type: EXPERIMENTAL
Intervention: Antiepileptic medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (normal neurologic examination, normal test results, no structural brain disease)
Number of subjects: 0
Study: 16095588

Group type: EXPERIMENTAL
Intervention: Exposure to ambiguous pronunciation followed by immediate testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure to Same or Different speaker for 25 min with no relevant input
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to Same or Different speaker for 25 min with one relevant input
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to Same or Different speaker for 25 min with both relevant inputs
Number of subjects: 0
Study: 12153606

Group type: EXPERIMENTAL
Intervention: Good metabolic control (HbA1c < or = 7.0)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Poor metabolic control (HbA1c > or = 8.0)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Correlation of basal plasma C‐peptide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Correlation of auc C‐peptide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multiple regression analyses
Number of subjects: 40
Study: 10455090

Group type: EXPERIMENTAL
Intervention: Simplified Peak Power (SPP) measured at rest and during maximum exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Delta SPP (difference between exercise and rest SPP)
Number of subjects: 40
Study: 8556905

Group type: EXPERIMENTAL
Intervention: 20-second delay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-minute delay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Providing reminders of the model and its relevance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior experience in using the model
Number of subjects: 0
Study: 2378793

Group type: EXPERIMENTAL
Intervention: Loxiglumide (2.5 mg kg‐1 in 10 min, followed by 5 mg kg‐1 h‐1 for 200 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 6
Study: 141634

Group type: EXPERIMENTAL
Intervention: Danazol 50 mg daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Danazol 100 mg daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Danazol 200 mg daily
Number of subjects: 30
Study: 31735553

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus gB-MF59 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30095776

Group type: EXPERIMENTAL
Intervention: 20‐mL buffered 1% lidocaine paracervical block
Number of subjects: 64

Group type: COMPARATOR
Intervention: No block (placebo)
Number of subjects: 64
Study: 27553916

Group type: EXPERIMENTAL
Intervention: Moderate-severe bladder dysfunction (n=49)
Number of subjects: 92

Group type: COMPARATOR
Intervention: None-mild bladder dysfunction (n=43)
Number of subjects: 92
Study: 25293475

Group type: EXPERIMENTAL
Intervention: GRVprototype
Number of subjects: 37

Group type: COMPARATOR
Intervention: IBP
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: IGP
Number of subjects: 37
Study: 23206440

Group type: EXPERIMENTAL
Intervention: Shen-Mai-San (SMS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18722681

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study: 17548525

Group type: EXPERIMENTAL
Intervention: Attitude-expressive goal made salient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High time pressure with attitude-expressive goal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bias at exposure
Number of subjects: 0
Study: 15766446

Group type: EXPERIMENTAL
Intervention: Coronary revascularization during hospitalization
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Aspirin administration
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Heparin administration
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors administration
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Beta-blockers administration
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors administration
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Statins administration
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Final diagnosis of angina
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Final diagnosis of myocardial infarction
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Final diagnosis of other conditions
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Mortality at 28 days
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Mortality at 6 months
Number of subjects: 1877
Study: 14625173

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 64
Study: 11114686

Group type: EXPERIMENTAL
Intervention: Trial milk with added long-chain polyunsaturated fatty acids (LCPs)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard formula milk
Number of subjects: 140
Study: 9026373

Group type: EXPERIMENTAL
Intervention: 12.5 mg Tianeptine (TIA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 25 mg Tianeptine (TIA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 mg Fluvoxamine (FLU)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1791622

Group type: EXPERIMENTAL
Intervention: Cynical hostility (measured by Cook and Medley Hostility Scale) during discussion task with incentive to exert control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cynical hostility (measured by Cook and Medley Hostility Scale) during discussion task without incentive to exert control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cynical hostility (measured by Cook and Medley Hostility Scale)
Number of subjects: 0
Study: 6136793

Group type: EXPERIMENTAL
Intervention: Dietary advice and cholestyramine, nicotinic acid, or clofibrate depending on lipoprotein phenotype
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 24
Study: 30922594

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29030268

Group type: EXPERIMENTAL
Intervention: Topical vancomycin plus standard of care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 0
Study: 27797984

Group type: EXPERIMENTAL
Intervention: Non-blind HT arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blind HT arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-blind HT arm (higher education)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-blind HT arm (never-smokers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-blind HT arm (subjective symptoms)
Number of subjects: 0
Study: 24818210

Group type: EXPERIMENTAL
Intervention: Collagen sponge covering fresh sockets (group 1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Corticocancellous porcine bone graft (group 2)
Number of subjects: 23
Study: 21569111

Group type: EXPERIMENTAL
Intervention: 1550-nm non-ablative fractional photothermolysis (NFP) treatment; 4 sessions at 3-week intervals, energy: 15 mJ/MTZ, total density: 1048 MTZs/cm², density per pass: 131 MTZs/cm², total coverage: 20%
Number of subjects: 51

Group type: COMPARATOR
Intervention: Broad-spectrum sunscreen alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 1550-nm non-ablative fractional photothermolysis (NFP) treatment
Number of subjects: 51
Study: 19944418

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus tamoxifen
Number of subjects: 150

Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling
Number of subjects: 150
Study: 16876301

Group type: EXPERIMENTAL
Intervention: Dopaminergic agonist (piribedil 50 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15765306

Group type: EXPERIMENTAL
Intervention: Quadruple-drug regimen: zidovudine/lamivudine/abacavir/nevirapine
Number of subjects: 28
Study: 12394652

Group type: EXPERIMENTAL
Intervention: PAI‐1 activity (chromogenic substrate kinetic assay)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: PAI‐1 protein (enzyme‐linked immunosorbent assay)
Number of subjects: 170
Study: 9573500

Group type: EXPERIMENTAL
Intervention: Presence of pulmonary infections (all etiologies mixed)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: History of previous opportunistic infections (all etiologies mixed)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Time since the diagnosis of acquired immunodeficiency syndrome more than 12 months
Number of subjects: 181
Study: 7523908

Group type: EXPERIMENTAL
Intervention: Sussex dataset
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Leiden dataset
Number of subjects: 500

Group type: COMPARATOR
Intervention: Vermont dataset
Number of subjects: 500

Group type: COMPARATOR
Intervention: Paris dataset
Number of subjects: 500
Study: 2975553

Group type: COMPARATOR
Intervention: Twice daily insulin regimen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Premixed 50:50 regimen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Premixed 30:70 regimen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Basal and prandial regimen
Number of subjects: 10
Study: 31498127

Group type: EXPERIMENTAL
Intervention: Opicapone 25mg
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Opicapone 50mg
Number of subjects: 1614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Open-label Opicapone
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Overall (Phase-3 clinical program)
Number of subjects: 1614
Study: 29496007

Group type: COMPARATOR
Intervention: Thermo-neutral beverage (TN)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Precooling with ice slurry beverage and iced towels (PRE)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Precooling with ice slurry beverage and iced towels plus ice slurry ingestion during cycling (PRE + MID)
Number of subjects: 7
Study: 26963434

Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR) before ischemic-reperfusion (I-R) injury
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR) after ischemic-reperfusion (I-R) injury
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR) with remote conditioning (preischemic)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR) with remote conditioning (postischemic)
Number of subjects: 20
Study: 25085598

Group type: EXPERIMENTAL
Intervention: Conversation Maps™ (CM) education
Number of subjects: 310

Group type: COMPARATOR
Intervention: Regular care (RC)
Number of subjects: 310
Study: 22414635

Group type: EXPERIMENTAL
Intervention: Endotoxin administration (0.8 ng/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 20807453

Group type: EXPERIMENTAL
Intervention: 4-hour interactive EBM workshop
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no workshop)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (workshop and control)
Number of subjects: 48
Study: 17645512

Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: gutta‐percha/AH Plus
Number of subjects: 90

Group type: COMPARATOR
Intervention: positive controls
Number of subjects: 90

Group type: COMPARATOR
Intervention: negative controls
Number of subjects: 90
Study: 16305007

Group type: EXPERIMENTAL
Intervention: Experimental chewable toothbrush
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control manual toothbrush
Number of subjects: 14
Study: 12243435

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF) during CPB
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (without MUF)
Number of subjects: 18
Study: 9836029

Group type: EXPERIMENTAL
Intervention: Morphine (2 mg loading dose, 1 mg in 4 ml bupivacaine 0.125%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl (50 micrograms loading dose, 20 micrograms in 4 ml bupivacaine 0.125%)
Number of subjects: 40
Study: 7984747

Group type: EXPERIMENTAL
Intervention: Trait Anxiety scale of Spielberger's State-Trait Anxiety Inventory for Children
Number of subjects: 157
Study: 3051044

Group type: EXPERIMENTAL
Intervention: 2 'Franol' tablets
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 'Franol' tablet
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2 placebo tablets
Number of subjects: 30
Study: 30037276

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 42
Study: 6111457

Group type: EXPERIMENTAL
Intervention: Propranolol on weight maintenance diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol during semistarvation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol on both diets
Number of subjects: 0
Study: 30883951

Group type: EXPERIMENTAL
Intervention: Intraosseous anaesthesia (IOA) delivered by QuickSleeper™
Number of subjects: 158

Group type: COMPARATOR
Intervention: Conventional infiltration anaesthesia (CIA)
Number of subjects: 158
Study: 28467015

Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation at 10 J/cm2 (B10)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation at 30 J/cm2 (B30)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation at 70 J/cm2 (B70)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation at 90 J/cm2 (B90)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation at 110 J/cm2 (B110)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (B0, not subjected to laser irradiation)
Number of subjects: 42
Study: 26525410

Group type: EXPERIMENTAL
Intervention: WATI enhanced with proactive, pushed tailored email motivational messaging (messaging)
Number of subjects: 4789

Group type: EXPERIMENTAL
Intervention: WATI with messaging further enhanced with personal secure messaging with a tobacco treatment specialist and an online support group (personalized)
Number of subjects: 4789

Group type: COMPARATOR
Intervention: State-of-the-art tailored WATI control
Number of subjects: 4789

Group type: EXPERIMENTAL
Intervention: ePortal implementation
Number of subjects: 4789